Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pearl Therapeutics IncfiledCriticalPearl Therapeutics Inc
Priority to ECSP13013082priorityCriticalpatent/ECSP13013082A/en
Publication of ECSP13013082ApublicationCriticalpatent/ECSP13013082A/en
Composiciones, métodos y sistemas se proporcionan para la administración pulmonar o nasal de dos o más agentes activos a través de un inhalador de dosis medida. En una forma de realización, las composiciones incluyen un medio de suspensión, partículas de agente activo, y las partículas en suspensión, en el que las partículas de agente activo y partículas en suspensión forman una cosuspensión en el medio de suspensión.Compositions, methods and systems are provided for pulmonary or nasal administration of two or more active agents through a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspended particles, in which the active agent particles and suspended particles form a cosuspension in the suspension medium.
ECSP130130822013-12-132013-12-13
COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF TWO OR MORE ACTIVE AGENTS
ECSP13013082A
(en)
Combination pharmaceutical product in the form of dry powder for administration by means of an inhaler comprising a umeclidinium salt of a defined group and 100 mcg / dose of fluticasone furoate, without other additional assets; use for the treatment of inflammatory or respiratory diseases.
Pharmaceutical composition for inhalation comprising aclidinium, with lactose, which provides a dose of 322 ug of free base and approx. 140 ug of aclidinium bromide; a method to treat a respiratory condition selected from asthma and epoc; use of the composition; and a calibrated dry powder inhaler device comprising it